Shufro Rose & Co’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $346K | Hold |
5,700
| – | – | 0.02% | 222 |
|
|
2025
Q4 | $307K | Sell |
5,700
-2,800
| -33% | -$135K | 0.02% | 228 |
|
|
2025
Q3 | $518K | Hold |
8,500
| – | – | 0.04% | 177 |
|
|
2025
Q2 | $518K | Hold |
8,500
| – | – | 0.04% | 175 |
|
|
2025
Q1 | $518K | Sell |
8,500
-60
| -0.7% | -$3.5K | 0.04% | 177 |
|
|
2024
Q4 | $484K | Sell |
8,560
-450
| -5% | -$25.1K | 0.04% | 172 |
|
|
2024
Q3 | $374K | Hold |
9,010
| – | – | 0.03% | 210 |
|
|
2024
Q2 | $374K | Buy |
9,010
+250
| +3% | +$11.2K | 0.03% | 210 |
|
|
2024
Q1 | $475K | Hold |
8,760
| – | – | 0.04% | 180 |
|
|
2023
Q4 | $508K | Hold |
8,760
| – | – | 0.05% | 157 |
|
|
2023
Q3 | $508K | Hold |
8,760
| – | – | 0.05% | 155 |
|
|
2023
Q2 | $560K | Hold |
8,760
| – | – | 0.05% | 154 |
|
|
2023
Q1 | $607K | Sell |
8,760
-1,356
| -13% | -$95.6K | 0.06% | 151 |
|
|
2022
Q4 | $728K | Buy |
10,116
+552
| +6% | +$41.6K | 0.06% | 133 |
|
|
2022
Q3 | $680K | Buy |
9,564
+738
| +8% | +$53.5K | 0.07% | 134 |
|
|
2022
Q2 | $680K | Buy |
8,826
+34
| +0.4% | +$2.59K | 0.06% | 140 |
|
|
2022
Q1 | $642K | Sell |
8,792
-90
| -1% | -$6.04K | 0.05% | 157 |
|
|
2021
Q4 | $554K | Hold |
8,882
| – | – | 0.04% | 172 |
|
|
2021
Q3 | $526K | Sell |
8,882
-2,927
| -25% | -$193K | 0.04% | 164 |
|
|
2021
Q2 | $789K | Sell |
11,809
-417,184
| -97% | -$27.2M | 0.06% | 130 |
|
|
2021
Q1 | $27.1M | Sell |
428,993
-13,535
| -3% | -$842K | 2.15% | 14 |
|
|
2020
Q4 | $27.4M | Sell |
442,528
-5,093
| -1% | -$313K | 2.3% | 13 |
|
|
2020
Q3 | $27M | Sell |
447,621
-775
| -0.2% | -$46.6K | 2.6% | 12 |
|
|
2020
Q2 | $26.4M | Sell |
448,396
-3,042
| -0.7% | -$182K | 2.6% | 10 |
|
|
2020
Q1 | $25.2M | Sell |
451,438
-8,150
| -2% | -$498K | 3% | 6 |
|
|
2019
Q4 | $29.5M | Sell |
459,588
-7,332
| -2% | -$420K | 2.66% | 6 |
|
|
2019
Q3 | $23.7M | Sell |
466,920
-1,790
| -0.4% | -$84.1K | 2.34% | 8 |
|
|
2019
Q2 | $21.3M | Sell |
468,710
-4,355
| -0.9% | -$203K | 2.07% | 9 |
|
|
2019
Q1 | $22.6M | Sell |
473,065
-116,262
| -20% | -$5.79M | 2.26% | 8 |
|
|
2018
Q4 | $30.6M | Sell |
589,327
-7,913
| -1% | -$425K | 3.39% | 4 |
|
|
2018
Q3 | $37.1M | Buy |
597,240
+971
| +0.2% | +$57.6K | 3.44% | 4 |
|
|
2018
Q2 | $33M | Buy |
596,269
+14,715
| +3% | +$795K | 3.15% | 4 |
|
|
2018
Q1 | $36.8M | Sell |
581,554
-3,599
| -0.6% | -$232K | 3.63% | 4 |
|
|
2017
Q4 | $35.9M | Sell |
585,153
-2,737
| -0.5% | -$171K | 3.53% | 3 |
|
|
2017
Q3 | $37.5M | Buy |
587,890
+5,298
| +0.9% | +$309K | 3.77% | 2 |
|
|
2017
Q2 | $32.5M | Buy |
582,592
+9,786
| +2% | +$533K | 3.47% | 4 |
|
|
2017
Q1 | $31.1M | Buy |
572,806
+111,326
| +24% | +$6.11M | 3.36% | 5 |
|
|
2016
Q4 | $27M | Buy |
461,480
+448,670
| +3,502% | +$24.5M | 3.01% | 7 |
|
|
2016
Q3 | $691K | Buy |
12,810
+55
| +0.4% | +$3.53K | 0.08% | 130 |
|
|
2016
Q2 | $938K | Sell |
12,755
-1,000
| -7% | -$70.7K | 0.1% | 114 |
|
|
2016
Q1 | $879K | Buy |
13,755
+1,000
| +8% | +$63.1K | 0.1% | 126 |
|
|
2015
Q4 | $877K | Hold |
12,755
| – | – | 0.1% | 123 |
|
|
2015
Q3 | $755K | Buy |
12,755
+105
| +0.8% | +$6.66K | 0.09% | 128 |
|
|
2015
Q2 | $841K | Hold |
12,650
| – | – | 0.09% | 131 |
|
|
2015
Q1 | $815K | Hold |
12,650
| – | – | 0.08% | 133 |
|
|
2014
Q4 | $746K | Hold |
12,650
| – | – | 0.08% | 136 |
|
|
2014
Q3 | $647K | Hold |
12,650
| – | – | 0.07% | 152 |
|
|
2014
Q2 | $613K | Hold |
12,650
| – | – | 0.06% | 157 |
|
|
2014
Q1 | $657K | Sell |
12,650
-200
| -2% | -$10.6K | 0.07% | 144 |
|
|
2013
Q4 | $682K | Hold |
12,850
| – | – | 0.07% | 137 |
|
|
2013
Q3 | $594K | Hold |
12,850
| – | – | 0.07% | 140 |
|
|
2013
Q2 | $574K | Buy |
+12,850
| New | +$558K | 0.07% | 143 |
|
Other funds holding BMY
VCM
VPM
Shufro Rose & Co's BMY Position: Q1 2026 in Review
Shufro Rose & Co held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 5,700 shares worth $346K. The position accounts for 0.02% of the portfolio, ranked #222.
Shufro Rose & Co first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.5M in Q3 2017. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Shufro Rose & Co held 5,700 shares of Bristol-Myers Squibb worth $346K as of Q1 2026.
- Shufro Rose & Co left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.02% of Shufro Rose & Co's portfolio in Q1 2026, its #222 holding.
- Shufro Rose & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Shufro Rose & Co's Bristol-Myers Squibb position peaked at $37.5M in Q3 2017.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.